Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712953 | 0.85 | MAPT (0.58) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12706346 | 0.83 | MAPT (0.60) | MAPTALDH1A1POLBCYP3A4CYP2D6 | |
| SCHEMBL21480659 | 0.82 | MAPT (0.64) | MAPTALDH1A1POLBCYP3A4CYP2D6 | |
| SCHEMBL446501 | 0.82 | MAPT (0.64) | MAPTALDH1A1POLBCYP3A4CYP2D6 | |
| SCHEMBL16809642 | 0.81 | MAPT (0.68) | MAPTALDH1A1POLBCYP3A4CYP2D6 | |
| SCHEMBL5010663 | 0.81 | MAPT (0.68) | MAPTALDH1A1POLBCYP3A4CYP2D6 | |
| SCHEMBL1747043 | 0.81 | MAPT (0.58) | MAPTALDH1A1POLBCYP3A4CYP2D6 | |
| SCHEMBL8891623 | 0.81 | MAPT (0.60) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2375356 | 0.81 | MAPT (0.60) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4221 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| US-9765016-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150361029-A1 | S1P MODULATING AGENTS | BIOGEN MA INC. | 2015-12-17 | — | — | US | disclosed |
| WO-2014120764-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | MAPT 4473/4885ALDH1A1 1682/4885POLB 4614/4885 |
| US-20150361029-A1 | S1P MODULATING AGENTS | S1PR3, S1PR5, S1PR1 | MAPT 4747/4885ALDH1A1 4396/4885POLB 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.